Recalls & Warnings April 25, 2017 Soylent Powder Recalled Due to Allergen Risk On April 24, 2017, Soylent issued a recall of 890 boxes (containing 7 x 15 oz pouches) of Soylent 1.8 Powder, because the product may contain undeclared milk
FDA-approved semaglutide is never dosed in units, and using incorrect measurements significantly increases the risk of dangerous medication errors including overdose
From a market perspective, the demand for antifungal drugs continues to rise: The market is expected to expand at a compound annual growth rate (CAGR) of 2.81% from 2020 to 2033, with a size of 14.09 billion US dollars in 2024, expected to rise to 14.48 billion US dollars in 2025, and reach 18.08 billion US dollars by 2033 ( Figure 1 ) (Insights, 2025).However, the development and application of antifungal drugs face numerous challenges (Fisher et al., 2018
Three mechanisms are most commonly implicated: rapid weight loss, nutritional deficiencies, and caloric restriction
This can lead to side effects such as extreme fatigue, hunger pangs, and lightheadedness